Journal for immunotherapy of cancer · 2025
FXR-mediated antigen-specific CD8+ T cell enhances antitumor immunity in intrahepatic cholangiocarcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Shanshan, Liang Zhixing, Zhu Lisi, Zheng Yuhao, Yu Haoyuan, Ye Shusen, Liang Texi, Huang Linzi, Ouyang Jiayi, Cao Yingjiao, Ye Lilin, Ye Linsen
Аннотация
BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) offers limited opportunities for surgical treatment, and advanced-stage patients exhibit poor responses to immunotherapy. Therefore, the exploration of new therapeutic strategies is of paramount importance. The farnesoid X receptor (FXR) is a nuclear receptor that has been reported to regulate immune cells in recent years. However, whether FXR can regulate CD8+ T cells to affect tumor development remains unknown.
METHODS: The function of FXR in CD8+ T cell-mediated antitumor immunity was assessed using spontaneous murine ICC models in systemic Nr1h4-knockout, and T cell-specific conditional knockout mice, with immune phenotyping performed by multicolor flow cytometry. The tumor antigen-specific CD8+ T response was tracked by tetramer staining and adoptive transfer of OT-1 T cells. The regulatory mechanism of FXR was confirmed using RNA sequencing, Chromatin Immunoprecipitation sequencing (ChIP-seq), Chromatin Immunoprecipitation polymerase chain reaction (ChIP-PCR), and luciferase reporter assays. The translational therapeutic potential was evaluated by administration of the FXR inhibitor ursodeoxycholic acid (UDCA), both as monotherapy and in combination with anti-programmed death-ligand 1 (PD-L1) blockade, in murine models and ex vivo using patient-derived tumor fragments.
RESULTS: FXR was specifically overexpressed in exhausted CD8+ tumor-infiltrating lymphocytes in both human and murine ICC. FXR ablation enhanced CD8+ T-cell effector function, proliferation, and stem-like progenitor capacity, leading to potent tumor control. Mechanistically, FXR transcriptionally upregulated the exhaustion marker LAG3 by directly binding to its promoter. Pharmacological inhibition of FXR with UDCA reversed T-cell exhaustion, and synergized with anti-PD-L1 therapy to significantly suppress tumor growth and enhance tumor cell apoptosis in murine models and human ICC ex vivo cultures.
CONCLUSIONS: Together, these data identify FXR as an immune checkpoint and support repurposing UDCA for ICC immunotherapy.
METHODS: The function of FXR in CD8+ T cell-mediated antitumor immunity was assessed using spontaneous murine ICC models in systemic Nr1h4-knockout, and T cell-specific conditional knockout mice, with immune phenotyping performed by multicolor flow cytometry. The tumor antigen-specific CD8+ T response was tracked by tetramer staining and adoptive transfer of OT-1 T cells. The regulatory mechanism of FXR was confirmed using RNA sequencing, Chromatin Immunoprecipitation sequencing (ChIP-seq), Chromatin Immunoprecipitation polymerase chain reaction (ChIP-PCR), and luciferase reporter assays. The translational therapeutic potential was evaluated by administration of the FXR inhibitor ursodeoxycholic acid (UDCA), both as monotherapy and in combination with anti-programmed death-ligand 1 (PD-L1) blockade, in murine models and ex vivo using patient-derived tumor fragments.
RESULTS: FXR was specifically overexpressed in exhausted CD8+ tumor-infiltrating lymphocytes in both human and murine ICC. FXR ablation enhanced CD8+ T-cell effector function, proliferation, and stem-like progenitor capacity, leading to potent tumor control. Mechanistically, FXR transcriptionally upregulated the exhaustion marker LAG3 by directly binding to its promoter. Pharmacological inhibition of FXR with UDCA reversed T-cell exhaustion, and synergized with anti-PD-L1 therapy to significantly suppress tumor growth and enhance tumor cell apoptosis in murine models and human ICC ex vivo cultures.
CONCLUSIONS: Together, these data identify FXR as an immune checkpoint and support repurposing UDCA for ICC immunotherapy.